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Summary
Background Lung function measures reﬂ ect the physiological state of the lung, and are essential to the diagnosis of 
chronic obstructive pulmonary disease (COPD). The SpiroMeta-CHARGE consortium undertook the largest genome-
wide association study (GWAS) so far (n=48 201) for forced expiratory volume in 1 s (FEV1) and the ratio of FEV1 to 
forced vital capacity (FEV1/FVC) in the general population. The lung expression quantitative trait loci (eQTLs) study 
mapped the genetic architecture of gene expression in lung tissue from 1111 individuals. We used a systems genetics 
approach to identify single nucleotide polymorphisms (SNPs) associated with lung function that act as eQTLs and 
change the level of expression of their target genes in lung tissue; termed eSNPs.
Methods The SpiroMeta-CHARGE GWAS results were integrated with lung eQTLs to map eSNPs and the genes and 
pathways underlying the associations in lung tissue. For comparison, a similar analysis was done in peripheral blood. 
The lung mRNA expression levels of the eSNP-regulated genes were tested for associations with lung function 
measures in 727 individuals. Additional analyses identiﬁ ed the pleiotropic eﬀ ects of eSNPs from the published 
GWAS catalogue, and mapped enrichment in regulatory regions from the ENCODE project. Finally, the Connectivity 
Map database was used to identify potential therapeutics in silico that could reverse the COPD lung tissue gene 
signature.
Findings SNPs associated with lung function measures were more likely to be eQTLs and vice versa. The integration 
mapped the speciﬁ c genes underlying the GWAS signals in lung tissue. The eSNP-regulated genes were enriched for 
developmental and inﬂ ammatory pathways; by comparison, SNPs associated with lung function that were eQTLs in 
blood, but not in lung, were only involved in inﬂ ammatory pathways. Lung function eSNPs were enriched for 
regulatory elements and were over-represented among genes showing diﬀ erential expression during fetal lung 
development. An mRNA gene expression signature for COPD was identiﬁ ed in lung tissue and compared with the 
Connectivity Map. This in-silico drug repurposing approach suggested several compounds that reverse the COPD 
gene expression signature, including a nicotine receptor antagonist. These ﬁ ndings represent novel therapeutic 
pathways for COPD.
Interpretation The system genetics approach identiﬁ ed lung tissue genes driving the variation in lung function and 
susceptibility to COPD. The identiﬁ cation of these genes and the pathways in which they are enriched is essential to 
understand the pathophysiology of airway obstruction and to identify novel therapeutic targets and biomarkers for 
COPD, including drugs that reverse the COPD gene signature in silico.
Funding The research reported in this article was not speciﬁ cally funded by any agency. See Acknowledgments for a 
full list of funders of the lung eQTL study and the Spiro-Meta CHARGE GWAS.
Introduction
Pulmonary function measures reﬂ ect the normal and 
pathological state of the lungs. The most commonly used 
measures are the forced expiratory volume in 1 s (FEV1) 
and the ratio of FEV1 to forced vital capacity (FEV1/FVC). 
These measurements are integral to th e diagnosis of 
chronic obstructive pulmonary disease (COPD), and are 
also important long-term predictors of population 
morbidity and all-cause mortality.1 Pulmonary function is 
determined by both environmental and genetic factors. 
Tobacco smoking is the major environmental risk factor 
for reduced pulmonary function. The genetic 
contribution to pulmonary function is well established, 
with estimates of heritability for FEV1 as high as 50%.2,3
The SpiroMeta consortium and the Consortium of 
Heart and Aging Research in Genomic Epidemiology 
(CHARGE) have published several genome-wide 
association studies (GWAS) that identiﬁ ed 26 loci 
associated with FEV1 and FEV1/FVC in the general 
population.4–6 Although these ﬁ ndings provide new 
insights into the genetic architecture of lung function, the 
exact genes and biological mechanisms underlying these 
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associations remain largely unclear. Single nucleotide 
polymorphisms (SNPs) can determine phenotypic traits 
by altering the quantity or function of the mRNA or 
protein for which the gene codes, or both.7 Recent studies 
suggest that for complex traits, SNPs in regulatory regions 
that control the level of gene expression are over-
represented in GWAS ﬁ ndings compared with coding 
variants.8,9 Genetic loci that control gene expression are 
called expression quantitative trait loci (eQTLs) and can be 
identiﬁ ed by testing SNPs for association with mRNA or 
protein expression.10 Gene regulation is often tissue-
speciﬁ c,11,12 and hence to make meaningful discoveries of 
eQTLs for lung function and COPD, it is informative to 
study the genetic control of lung-speciﬁ c gene expression. 
The lung eQTL consortium identiﬁ ed 468 300 cis-acting 
(aﬀ ecting expression of genes within 1 Mb of the transcript 
start site) and 16 677 trans-acting (further than 1 Mb away 
or on a diﬀ erent chromosome) eQTLs out of 2 598 263 
SNPs at a 10% false discovery rate (FDR) in a large-scale 
eQTL mapping study of 1111 human lung tissues.13–17
Systems genetics enables a global analysis of molecular 
mechanisms by integrating data for genetic variation with 
intermediate phenotypes such as gene expression (mRNA, 
protein or both), epigenetics changes, or metabolite levels 
and examining how they interact and converge to alter 
complex traits and diseases.18–22 We hypothesised that a 
subset of SNPs identiﬁ ed in the SpiroMeta-CHARGE 
GWAS meta-analysis of about 48 000 individuals5 aﬀ ect 
variation in lung function by acting as eQTLs to change 
the level of expression of their target genes in the lung. In 
this study, a systems genetics approach was used to 
overlap results from the SpiroMeta-CHARGE GWAS 
meta-analysis with the lung eQTLs identiﬁ ed by the lung 
eQTL consortium and to leverage the SNP-mRNA-lung 
function correlations to unravel genes and molecular 
mechanisms underlying lung function variation.
Methods
Study design
The overall study design is shown in ﬁ gure 1. The ﬁ rst 
step was the identiﬁ cation of lung function eSNPs: SNPs 
with an association p value (pGWAS) <0·001 that act as cis or 
trans lung eQTLs at an FDR of less than 10%. This step 
formed the basis for all downstream analyses. At the SNP 
level, the enrichment of SpiroMeta-CHARGE GWAS hits 
for lung eQTLs was calculated, and the expected direction 
of association of mRNA with lung function was inferred 
given the SNP associations with lung function and 
mRNA. eSNPs were additionally assessed for functional 
annotations in the Encyclopedia of DNA Elements 
(ENCODE) dataset, and for evidence of pleiotropy in the 
National Human Genome Research Institute (NHGRI) 
human GWAS Catalog. At the gene level, lung function 
eSNP-regulated genes in lung tissue were tested for 
enrichment in pathways and gene ontology processes. 
Then the pathways were compared with lung function-
related genes regulated by eSNPs in blood. The potential 
developmental role of lung function genes was tested by 
comparison with a study of the transcriptome in human 
fetal lung. The levels of expression of lung function genes 
in lung tissue were tested for association with lung 
function measures and COPD in participants from the 
eQTL study. Finally, the Connectivity Map (CMap) 
database was used to identify potential therapeutics in 
silico for COPD using the disease’s gene expression 
signature in lung tissue.
Study cohorts
The methods and participant characteristics of the 
SpiroMeta-CHARGE lung function GWAS have been 
described in detail elsewhere.5 Brieﬂ y, meta-analyses for 
cross-sectional lung function measures were undertaken 
for approximately 2·5 million HapMap II imputed SNPs 
Research in context
Evidence before this study
We searched PubMed for reports published in English before Nov 1, 
2014. We used the search terms “genome-wide association” and 
“eQTL” and “lung function” or “FEV1” or “FEV1/FVC” or “COPD”. We 
additionally searched the published genome-wide association 
study (GWAS) catalogue. At the time of our search, no large-scale 
integration reports of GWAS and lung expression quantitative trait 
loci (eQTLs) existed for lung function measures or chronic 
obstructive pulmonary disease (COPD). Evidence from GWAS in 
other diseases suggests that integration of GWAS results with 
eQTLs in relevant tissue can identify the genes most likely to be 
responsible for the associations and unravel the molecular 
mechanisms underlying variation in lung function.
Added value of this study
We show to our knowledge for the ﬁ rst time that single 
nucleotide polymorphisms (SNPs) associated with lung 
function are enriched for lung eQTLs. This study identiﬁ ed a 
large number of SNPs/genes that determine the variation in 
lung function measures; these were enriched in developmental 
and inﬂ ammatory pathways. Lung function genes are 
supported by evidence from GWAS, eQTL, and mRNA 
associations with lung function and as such represent potential 
therapeutic and biomarker targets. Furthermore, we used the 
resulting lung gene expression signature to identify potential 
novel COPD drugs with an in-silico drug repositioning 
approach.
Implications of all the available evidence
Our study has identiﬁ ed genes underlying the variation in lung 
function in lung tissue, representing testable hypotheses for 
future in-vitro and in-vivo studies. Our results serve as a unique 
resource to the larger scientiﬁ c community interested in the 
pathogenesis and genetics of obstructive lung diseases.
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across 23 individual GWAS with a combined sample size 
of 48 201 adult individuals of European ancestry. The 
analyses of FEV1 and FEV1/FVC were adjusted for age, 
age2, sex, and height, and where appropriate study centre 
and ancestry principal components as covariates.
The methods and participant characteristics of the lung 
tissue eQTL study have been described in detail 
elsewhere.13 Brieﬂ y, lung eQTLs were derived from a 
meta-analysis of non-tumour lung tissue eQTLs from 
1111 patients who underwent lung resection surgery at 
three participating sites: the University of British 
Columbia Centre for Heart and Lung Innovation 
(Vancouver, Canada; n=339), Laval University (Quebec 
City, Canada; n=409) and the University of Groningen 
(Groningen, Netherlands; n=363). The expression data 
are available at NCBI Gene Expression Omnibus 
repository (accession number GSE23546). Genotyping 
was performed on DNA extracted from blood or lung 
tissue with the Illumina Human1M-Duo BeadChip array, 
and imputation was performed using the HapMap II 
reference panel providing eQTL data for 2 598 263 million 
SNPs. With a Benjamini-Hochberg 10% FDR threshold, 
the study identiﬁ ed 468 300 cis (18% of all SNPs tested) 
and 16 677 trans eQTLs representing 0·64% of all SNPs 
tested.
Appropriate ethics approval for the lung function 
GWAS and the lung eQTL studies was received from all 
participating institutions.
Analyses and statistical analyses
To integrate the SNPs that were associated with FEV1 or 
FEV1/FVC, or both, with gene expression in the lung, we 
ﬁ rst merged the 468 300 cis-eQTLs and the 16 677 trans-
eQTLs with SNPs in the SpiroMeta and CHARGE GWAS 
(2 419 122 SNPs at N eﬀ ective >50%). Merged SNPs were 
then ﬁ ltered to select those with a pGWAS<0·001 for 
association with FEV1 or FEV1/FVC. Throughout this 
report we refer to SNPs associated with FEV1 or FEV1/FVC 
that act as eQTLs as lung function eSNPs, and the genes 
regulated by these SNPs as lung function eSNP-regulated 
genes. Fold enrichments were calculated from the 
merged results and signiﬁ cance of the enrichment of 
eSNPs among SpiroMeta-CHARGE GWAS results was 
ca culated by Fisher’s exact test.
The lung function eSNP-regulated genes were tested 
for enrichment in gene ontology biological processes and 
pathways with the Web-based Gene Set Analysis Toolkit 
(WebGestalt).23
For lung function eSNP-regulated genes, the relation 
between mRNA expression levels and lung function 
measures was examined in 727 of the 1111 participants in 
the lung eQTL study. The subset of participants who 
were selected had the appropriate measures of lung 
function and did not have a diagnosis (other than COPD 
or lung cancer) likely to aﬀ ect lung function. Table 1 shows 
the demographics of this subgroup of participants. A 
linear regression analysis of the level of expression of 
each probe set on FEV1 and FEV1/FVC, adjusted for age, 
sex, height, and smoking status was done for each of 
three cohorts separately, followed by meta-analysis.
The allelic eﬀ ect of the eSNPs on FEV1 and FEV1/FVC 
from the GWAS, and on mRNA from the lung eQTL 
study was used to infer the predicted direction of eﬀ ect 
between the mRNA and lung function measures; we 
refer to this as the expected direction. Independently, we 
regressed the mRNA levels of lung function eSNP-
regulated genes on FEV1 and FEV1/FVC in the subset of 
727 participants of the eQTL study, and we refer to the 
direction of eﬀ ect for this association as the observed 
direction. For lung function eSNP-regulated probe sets 
that show signiﬁ cant mRNA association with lung 
function measures, we investigated whether the observed 
direction of eﬀ ect was either concordant or discordant 
with the expected direction.
To identify potential compounds that could reverse (or 
induce) COPD-associated genes, the Connectivity Map 
online tool from the Broad Institute was used.24 The 
Connectivity Map hosts a publically available database of 
transcriptional proﬁ les produced by existing drugs. 
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Figure 1: Study design
Lung function eSNPs were deﬁ ned as GWAS SNPs with pGWAS<0·001 that act as cis or trans lung eQTLs passing the 
10% FDR. The enrichment of SpiroMeta-CHARGE GWAS for eSNPs was calculated. The expected direction of eﬀ ect 
of mRNA on lung function was inferred. Lung function eSNP-regulated genes in lung tissue were tested for 
pathway and gene ontology processes enrichment, and the pathways were compared with blood lung function 
eSNP-regulated genes. The level of expression of lung function eSNP-regulated genes was tested for association 
with lung function measures in participants from the eQTL study. The lung function eSNPs and their target genes 
were tested for ENCODE functional enrichment and for transcription factor enrichment in the promoters of lung 
function eSNP-regulated genes. Furthermore, lung function eSNPs were integrated with the National Human 
Genome Research Institute human GWAS Catalog, to identify pleiotropic associations. The potential 
developmental role of lung function eSNP-regulated genes was tested by comparison with a study of the 
transcriptome of human fetal lung. Finally, the expression pattern of eSNP-regulated genes that were associated 
with COPD was interrogated using the Connectivity Map database to identify potential therapeutics in silico. 
eQTLs=expression quantitative trait loci. FDR=false discovery rate. GWAS=genome-wide association studies. 
SNP=single nucleotide polymorphisms. 
SpiroMeta-
CHARGE
2 419 122 SNPs
Lung eQTLs
468 300 cis
16 677 trans
Lung
function
eSNPs 
Lung function eSNPs
Test mRNA levels for association with lung function 
in the eQTL study
Assess for functional annotations in ENCODE
Lung function eSNP-regulated genes
Test for pathway enrichment and comparison
with blood eSNPs 
 Assess for pleiotropy in the GWAS Catalog  Use Connectivity Map to identify in-silico therapeutics
for COPD
Compare with human fetal lung transcriptomeInfer direction of eﬀect of mRNA on lung function 
Calculate enrichment among GWAS SNPs
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The database contains more than 7000 genome-wide 
transcriptomes from cultured human cells treated with 
1309 bioactive compounds. Since the Connectivity Map 
expects a gene signature of upregulated and down-
regulated genes as input, we tested the expression levels 
of lung function eSNP-regulated genes for diﬀ erential 
expression between COPD cases (n=428) and controls 
(n=330) in individuals from the eQTL study. 51 lung 
function eSNP-regulated genes associated with COPD at 
nominal p values of <0·05 were mapped into Aﬀ ymetrix 
platform HG-U133A probe set IDs (33 genes were 
remapped) to be used as input for the Connectivity Map 
to query compounds that could reverse or augment the 
airway obstruction gene signature.
Lung function eSNPs were tested for pleiotropy (a SNP 
that inﬂ uences multiple diseases/traits) by integrating 
them with the NHGRI GWAS Catalog.25 The ENCODE 
ChIP-Seq Signiﬁ cance Tool26 was used to gain insights 
into what transcription factors were enriched in the 
promoters of lung function eSNP-regulated genes. At 
the SNP level, lung function eSNPs were tested for 
enrichment in ENCODE functional annotations with 
HaploReg v2 publically available software.27
 We assessed whether SpiroMeta-CHARGE SNPs with 
pGWAS<0·001 act as cis-eQTLs meeting 10% FDR in non-
transformed peripheral blood mononuclear cells 
(PBMCs) obtained from 5311 European participants.28 An 
eQTL was deﬁ ned as cis-acting if the SNP position is less 
than 250 Kb away from the midpoint of the probe.
All statistical analyses were done with R version 3.0.1. 
Additional and detailed methods are available in the 
appendix (pp 3–6).
Role of the funding source
The funding sources had no roles in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Of the 2 419 122 SNPs investigated in the SpiroMeta-
CHARGE GWAS, 440 665 were cis-eQTLs, and 15 135 were 
trans-eQTLs that passed the 10% FDR in the lung eQTL 
study. Figure 2 shows a quantile-quantile (Q-Q) plot of the 
SpiroMeta-CHARGE associations with FEV1 and 
FEV1/FVC for the cis-eQTLs and trans-eQTLs. The y axis 
represents the quantiles of the eQTLs’ associations with 
FEV1 or FEV1/FVC in the SpiroMeta-CHARGE GWAS, 
plotted against an expected distribution derived from the 
GWAS p values for all 2 419 122 SNPs. The plots show a 
large systematic deviation of p values for eQTLs compared 
with the GWAS association p values for all SNPs. Table 2 
shows that of the 440 665 cis-eQTLs, 3413 were associated 
with FEV1 and 2205 were associated with FEV1/FVC in the 
SpiroMeta-CHARGE GWAS study at pGWAS<0·001. Of the 
15 135 trans-eQTLs, 1568 were associated with FEV1 (38-fold 
enrichment) and 442 with FEV1/FVC (12·6-fold 
enrichment) at pGWAS<0·001. We refer to these eQTLs as 
lung function eSNPs. The enrichment is stronger for 
trans-eQTLs, possibly because of the more stringent 
statistical threshold needed to deﬁ ne a trans-eQTL. 
Enrichments at diﬀ erent pGWAS cutoﬀ s are shown in the 
appendix (pp 25–26). The deviation in the Q-Q plots and 
the enrichment in table 2 suggest that lung eQTLs are 
enriched for associations with lung function in the 
SpiroMeta-CHARGE GWAS, and vice versa. That a SNP is 
associated with both a lung function phenotype and with 
lung gene expression increases the likelihood that it is 
involved in a causal pathway,10 especially since most SNPs 
identiﬁ ed in GWAS do not aﬀ ect protein coding.
To validate these ﬁ ndings, lung eQTLs were overlapped 
with results from a GWAS meta-analysis for type 2 
diabetes from Morris and colleagues.29 The meta-analysis 
consisted of 12 171 cases of type 2 diabetes and 
56 862 controls across 12 GWAS from European descent 
populations. Similar analyses to the lung function GWAS 
overlap were done to obtain Q-Q plots for blood and lung 
type 2 diabetes eSNPs (appendix p 7). The Q-Q plot 
shows that the enrichment for lung function SNPs in 
lung tissue eQTLs is systematically diﬀ erent compared 
with that for type 2 diabetes.
Since baseline enrichment could be expected for 
GWAS SNPs proximal to genes irrespective of being 
eQTLs in the relevant tissue, a comparison was made of 
SpiroMeta-CHARGE SNPs within 1 Mb of known 
UBC (n=251) Laval (n=387) Groningen (n=89)
Age (years) 63·53 (10·22) 63·48 (9·74) 61·54 (9·74)
Sex (male) 119 (47%) 171 (44%) 33 (37%)
Body-mass index (kg/m²) 25·76 (5·4) 26·56 (5·26) 25·17 (4·09)
FEV1 % predicted 79·42 (23·06) 80·54 (19·04) 72·71 (24·77)
FEV1/FVC 67·76 (12·46) 67·42 (9·73) 63·07 (16·98)
COPD* 107 (43%) 204 (53%) 53 (60%)
Stage
1 (mild) 41 (38%) 80 (39%) 15 (28%)
2 (moderate) 57 (53%) 112 (55%) 28 (53%)
3 (severe) 2 (2%) 11 (5%) 2 (4%)
4 (very severe) 7 (7%) 1 (<1%) 8 (15%)
Non-COPD 123 (49%) 159 (41%) 32 (36%)
Smoking
Smoker 86 (34%) 87 (22%) 31 (35%)
Ex-smoker 150 (60%) 270 (70%) 53 (60%)
Non-smoker 15 (6%) 30 (8%) 5 (6%)
Pack-years smoked 43·02 (30·13) 44·54 (29·48) 36·18 (19·05)
Data are n (%) or mean (SD). UBC=University of British Columbia, Vancouver, Canada. Laval=Laval University, Quebec 
City, Canada. Groningen=Groningen University, Groningen, Netherlands. COPD=chronic obstructive pulmonary disease. 
FEV1=forced expiratory volume in 1 s. FEV1/FVC=ratio of FEV1 to forced vital capacity.*Numbers of patients with COPD 
and without COPD do not add up to the total sample size in each cohort; numbers of patients with unknown COPD 
status were 21 (8%) in UBC, 24 (6%) in Laval, and 4 (4%) in Groningen. 
Table 1: Demographics of 727 individuals in whom lung mRNA levels were tested for association with 
lung function
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genes to all SNPs. The Q-Q plots (appendix p 8) show a 
modest deviation for proximal SNPs but only for SNPs 
with low pGWAS. However, the deviation is less than what 
is seen in the Q-Q plots of lung eSNPs (ﬁ gure 2), 
suggesting that genomic distance alone does not 
explain the deviation noted for lung eSNPs and that 
this large deviation is driven by the tissue type used for 
eQTL discovery and its relevance to the phenotype 
under investigation.
The full list of lung function cis and trans eSNP-
regulated genes is provided in the appendix (pp 27–68). A 
Venn diagram illustrating the extent of overlap for cis and 
trans FEV1 and FEV1/FVC eSNP-regulated genes is 
shown in the appendix (p 9). For example, there are 
63 lung function cis eSNP-regulated genes associated 
with both FEV1 and FEV1/FVC.
Table 3 shows lung eQTL integration results for 50 SNPs 
within the 26 loci reported in three of the consortia’s 
published meta-analyses that met the genome-wide 
signiﬁ cance threshold.4-6 Of the 50 lung function-
associated SNPs reported in the three meta-analyses, 
25 (50%) act as lung eSNPs at 10% FDR. Table 3 shows the 
GWAS p values and the genes suggested to underlie the 
associations in the published reports (usually the closest 
gene), as well as the lung eQTL-regulated genes and 
the eQTL p values for the SNPs. For ten of the 25 eSNPs, 
the GWAS-suggested gene (based on SNP position) and 
the eSNP-regulated gene were the same. Another ten of 
the 25 eSNP-regulated genes were diﬀ erent from the ones 
suggested in the GWAS. For four of the 25, the eSNP 
regulated the expression of more than one gene, including 
the gene suggested by the GWAS. In these instances, the 
level of eQTL statistical signiﬁ cance with the alternative 
genes was usually stronger. Finally, one eSNP (rs2857595) 
regulated the expression of 11 genes, which did not include 
the GWAS suggested gene—NCR3 in this case.5 Some of 
the reported SNPs reside at the same locus and are in 
linkage disequilibrium.
The pathway analyses of lung function cis eSNP-
regulated genes identiﬁ ed several enriched gene 
ontology processes that were common for FEV1 and 
FEV1/FVC (ﬁ gure 3). These processes were related to 
development and inﬂ ammatory or immune responses 
such as natural killer T-cell diﬀ erentiation, immune 
system processes, and positive regulation of the 
immune system. No gene ontology processes were 
signiﬁ cantly enriched (at any FDR value) among the 
29 FEV1 and 21 FEV1/FVC trans-regulated genes. Cis and 
trans lung function eSNP-regulated genes were enriched 
for several Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways (appendix p 10 and p 23).
To test whether the genes and pathways identiﬁ ed by 
integration of the GWAS and lung eQTL data were 
unique to lung tissue, we compared the results with 
those derived from integration of the SpiroMeta-
CHARGE GWAS SNPs that had pGWAS<0·001 with cis-
eQTL data derived from non-transformed PBMCs 
reported in a study of 5311 participants.28 3002 (45%) of 
the 6615 FEV1-associated SNPs act as blood cis-eQTLs 
and 1958 (37%) of the 5239 FEV1/FVC-associated 
SNPs act as blood cis-eQTLs (appendix p 69). These 
SNPs regulate the expression of 306 and 276 blood 
FEV1 cis FEV1 trans FEV1/FVC cis FEV1/FVC trans
Number of eSNPs, n/N (%) 3413/6615 (52%) 1568/6615 (23%) 2205/5239 (42%) 442/5239 (8%)
Fold enrichment and p value 2·7* 37·9* 2·2* 12·6*
Number of eSNP-regulated 
probe sets
496 54 483 38
Number of eSNP-regulated 
genes
267 29 265 21
eSNPs refer to the SpiroMeta-CHARGE GWAS SNPs with pGWAS<0·001 acting as cis-eQTLs or trans-eQTLs at the 10% FDR. 
The number of genes reﬂ ects the conversion of probe sets to genes; on average there were two probe sets per gene. 
The table also shows the number of probe sets and genes regulated by eSNPs. The decrease in numbers between total 
eSNPs and eSNP-regulated probe sets reﬂ ects the fact that multiple eSNPs can be associated with the same probe set. 
The decrease in numbers from probe sets to genes reﬂ ects that the Aﬀ ymetrix platform used tested on average two 
probe sets per gene. eQTLs=expression quantitative trait loci. FDR=false discovery rate. FEV1=forced expiratory volume 
in 1 s. FEV1/FVC=ratio of FEV1 to forced vital capacity. GWAS=genome-wide association studies. SNP=single nucleotide 
polymorphisms. *Denotes the enrichment is signiﬁ cant with Fisher’s exact test p<2·2 × 10–¹⁶.
Table 2: Number of cis-acting and trans-acting eSNPs and their relation to genes
Figure 2: Quantile-quantile (Q-Q) plot of lung function pGWAS distribution for eSNPs versus lung function pGWAS 
distribution for all SNPs
On the y axis are quantiles of the distribution of lung function GWAS p values (pGWAS) for eSNPs that pass 10% FDR. On 
the x axis are the quantiles of the distribution of lung function GWAS p values for all 2 419 122 SNPs. The systematic 
deviation of the line from the expected distribution shows lung function associated SNPs are enriched for lung eQTLs. 
(A) FEV1 cis-eSNPs, (B) FEV1 trans-eSNPs, (C) FEV1/FVC cis-eSNPs, and (D) FEV1/FVC trans-eSNPs. eQTLs=expression 
quantitative trait loci. FDR=false discovery rate. FEV1=forced expiratory volume in 1 s. FEV1/FVC=ratio of FEV1 to forced 
vital capacity. GWAS=genome-wide association studies. SNP=single nucleotide polymorphisms.
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SNP Locus Lung function 
trait
Lung function 
GWAS p value*
GWAS-proposed gene eQTL-regulated gene eQTL p value Reference
1p36.13 rs2284746 1p36.13 FEV1/FVC 7·5 × 10–¹⁶ MFAP2 MFAP2 1·83 × 10–⁷ 5
1p36.13 rs2284746 1p36.13 FEV1/FVC 7·5 × 10–¹⁶ MFAP2 PADI2 2·31 × 10–¹⁰ 5
1q41 rs993925 1q41 FEV1/FVC 1·16 × 10–⁸ TGFB2 TGFB2 1·38 × 10–⁵ 5
2q35 rs2571445 2q35 FEV1 1·11 × 10−¹² TNS1 TNS1 1·95 × 10–⁵ 4
2q36.3  rs1435867 2q36.3 FEV1/FVC 1·53 × 10–⁵† PID1 ·· ·· 6
2q36.3 rs10498230 2q36.3 FEV1/FVC 1·46 × 10–⁵† PID1 ·· ·· 6
2q37.3 rs12477314 2q37.3 FEV1/FVC 1·68 × 10–¹² HDAC4 ·· ·· 5
3p24.2 rs1529672 3p24.2 FEV1/FVC 3·97 × 10–¹⁴ RARB ·· ·· 5
3q26.2 rs1344555 3q26.2 FEV1 2·65 × 10–⁵ MECOM ·· ·· 5
4q22.1 rs2869967 4q22.1 FEV1/FVC 1·91 × 10–⁷† FAM13A FAM13A 1·74 × 10–⁶ 6
4q22.1 rs6830970 4q22.1 FEV1/FVC 6·63 × 10–⁷† FAM13A ·· ·· 6
4q24 rs10516526 4q24 FEV1 2·18 × 10−²³ GSTCD NPNT 3·89 × 10–⁵ 4
4q24 rs17331332 4q24 FEV1 5·69 × 10–¹⁵ NPNT NPNT 6·73 × 10–⁶ 6
4q24 rs17036341 4q24 FEV1 2·18 × 10–¹⁵ NPNT NPNT 1·67 × 10–⁵ 6
4q24 rs11727189 4q24 FEV1 4·66 × 10–¹⁷ INTS12 NPNT 4·70 × 10–⁵ 6
4q24 rs17036090 4q24 FEV1 5·61 × 10–¹⁵ INTS12 ·· ·· 6
4q24 rs17036052 4q24 FEV1 1·83 × 10–¹⁵ ARHGEF38 (FLJ20184) ·· ·· 6
4q24 rs17035960 4q24 FEV1 9·42 × 10–¹⁴ ARHGEF38 (FLJ20184) ·· ·· 6
4q24 rs11097901 4q24 FEV1 3·26 × 10–¹⁶ GSTCD NPNT 3·85 × 10–⁵ 6
4q24 rs11728716 4q24 FEV1 7·20 × 10–¹⁶ GSTCD NPNT 2·11 × 10–⁵ 6
4q31.21 rs12504628 4q31.21 FEV1/FVC 6·48 × 10−¹³ HHIP HHIP 2·00 × 10–⁶ 4
4q31.21  rs1980057 4q31.21 FEV1/FVC 3·21 × 10–²⁰ HHIP HHIP 4·65 × 10–⁷ 6
4q31.22 rs1032295 4q31.22 FEV1/FVC 4·37 × 10–¹⁵ HHIP ·· ·· 6
5q15 rs153916 5q15 FEV1/FVC 2·12 × 10–⁸ SPATA9 RHOBTB3 5·77 × 10–¹⁶ 5
5q32 rs3995090 5q32 FEV1 4·29 × 10−⁹ HTR4 ·· ·· 4
5q33.1 rs6889822 5q33.1 FEV1 8·17 × 10−⁹ HTR4 FBXO38 4·33 × 10–⁵ 4
5q33.1 rs11168048 5q33.1 FEV1/FVC 1·08 × 10–¹¹ HTR4 ·· ·· 6
5q33.1 rs7735184 5q33.1 FEV1/FVC 6·23 × 10–¹¹ HTR4 ·· ·· 6
5q33.3 rs2277027 5q33.3 FEV1/FVC 9·93 × 10–¹¹ ADAM19 ADAM19 4·41 × 10–⁶ 6
5q33.3 rs1422795 5q33.3 FEV1/FVC 2·62 × 10–¹⁰ ADAM19 ·· ·· 6
6q21 rs2798641 6q21 FEV1/FVC 8·35 × 10–⁹ ARMC2 ·· ·· 5
6p22.1 rs6903823 6p22.1 FEV1 2·18 × 10–¹⁰ ZKSCAN3 (ZNF323) BTN3A2 2·26 × 10–¹⁹ 5
6p22.1 rs6903823 6p22.1 FEV1 2·18 × 10–¹⁰ ZKSCAN3 (ZNF323) HCG4P6 4·80 × 10–¹⁸ 5
6p22.1 rs6903823 6p22.1 FEV1 2·18 × 10–¹⁰ ZKSCAN3 (ZNF323) HLA-A 3·46 × 10–²⁸ 5
6p22.1 rs6903823 6p22.1 FEV1 2·18 × 10–¹⁰ ZKSCAN3 (ZNF323) PGBD1 2·48 × 10–⁸ 5
6p22.1 rs6903823 6p22.1 FEV1 2·18 × 10–¹⁰ ZKSCAN3 (ZNF323) ZFP57 1·39 × 10–²⁵ 5
6p22.1 rs6903823 6p22.1 FEV1 2·18 × 10–¹⁰ ZKSCAN3 (ZNF323) ZSCAN26 (ZNF187) 3·16 × 10–⁵ 5
6p22.1 rs6903823 6p22.1 FEV1 2·18 × 10–¹⁰ ZKSCAN3 (ZNF323) ZSCAN31 (ZNF323) 3·17 × 10–²⁰ 5
6p21.2 rs2395730 6p21.2 FEV1/FVC 7·98 × 10−⁸ DAAM2 ·· ·· 4
6p21.32 rs2070600‡ 6p21.32 FEV1/FVC 3·07 × 10−¹⁵ AGER AGER 1·30 × 10–⁵ 4
6p21.32 rs2070600‡ 6p21.32 FEV1/FVC 3·07 × 10−¹⁵ AGER HLA-DRB6 2·62 × 10–¹⁴ 4
6p21.32 rs2070600‡ 6p21.32 FEV1/FVC 3·07 × 10−¹⁵ AGER HLA-DRB1 2·21 × 10–⁶ 4
6p21.32 rs2070600‡ 6p21.32 FEV1/FVC 3·07 × 10−¹⁵ AGER AGER 4·09 × 10–⁶ 4
6p21.32 rs2070600‡ 6p21.32 FEV1/FVC 3·07 × 10−¹⁵ AGER HLA-DQA2 7·18 × 10–¹² 4
6p21.32 rs2070600‡ 6p21.32 FEV1/FVC 3·07 × 10−¹⁵ AGER HLA-DRB4 9·24 × 10–²² 4
6p21.32 rs2070600‡ 6p21.32 FEV1/FVC 3·07 × 10−¹⁵ AGER AGER 5·86 × 10–⁷ 4
6p21.32 rs10947233 6p21.32 FEV1/FVC 6·66 × 10–¹² PPT2 HLA-DRB6 1·06 × 10–¹¹ 6
6p21.32 rs10947233 6p21.32 FEV1/FVC 6·66 × 10–¹² PPT2 HLA-DQA2 2·10 × 10–⁹ 6
6p21.32 rs10947233 6p21.32 FEV1/FVC 6·66 × 10–¹² PPT2 AGER 1·92 × 10–⁵ 6
6p21.32 rs10947233 6p21.32 FEV1/FVC 6·66 × 10–¹² PPT2 HLA-DRB1 3·43 × 10–⁵ 6
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 APOM 7·79 × 10–⁶ 5
(Table 3 continues on next page)
For NCBI Gene Expression 
Omnibus see http://www.ncbi.
nlm.nih.gov/geo
For the Connectivity Map see 
http://www.broadinstitute.org/
cmap/
See Online for appendix
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eSNP-regulated genes for FEV1 and FEV1/FVC, 
respectively. A list of the blood eSNPs and the genes 
under their genetic control for both FEV1 and FEV1/FVC 
is provided in the appendix (pp 70–83). The Q-Q plots 
for blood cis-eSNPs are shown in the appendix (p 11), 
and for comparison we also show the Q-Q plot for lung 
eSNPs on the same graph. The plots show a deviation 
for FEV1 blood cis-eSNPs from the distribution of 
p values for the whole GWAS that is very similar to the 
lung FEV1 cis-eSNPs. Some FEV1/FVC blood cis-eSNPs 
have higher p values compared with the GWAS result 
and a very diﬀ erent distribution from FEV1/FVC lung 
eSNPs. Although many lung function eSNP-regulated 
genes overlapped between the two tissues, some were 
unique to either lung or blood (appendix p 12). For 
example, 88 FEV1 cis-regulated genes were common to 
both lung and blood, whereas 127 and 154 FEV1 cis 
genes were only under genetic control in lung and 
blood, respectively.
Similar to lung function eSNP-regulated genes derived 
from the lung tissue analysis, lung function eSNP-regulated 
genes derived from blood were enriched in processes 
related to development, maturation, and inﬂ ammatory 
processes (appendix p 13). To extend the analysis, we 
performed gene ontology process enrichment analyses on 
genes from three groups: lung-only regulated genes, blood-
only regulated genes, and shared lung and blood regulated 
genes. The results (appendix p 84) showed that lung 
function eSNP-regulated genes restricted to blood were 
enriched solely for inﬂ ammatory processes, whereas eSNP-
regulated genes in lung tissue and those shared between 
lung and blood were enriched for both developmental and 
inﬂ ammatory processes. In con cordance with these results, 
lung function eSNP-regulated genes were over-represented 
among genes diﬀ erentially expressed during human fetal 
lung development (appendix pp 86–116).
There were 868 unique lung function eSNP-regulated 
probe sets when overlap between FEV1 and FEV1/FVC, 
SNP Locus Lung function 
trait
Lung function 
GWAS p value*
GWAS-proposed gene eQTL-regulated gene eQTL p value Reference
(Continued from previous page)
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 ATP6V1G2 1·32 × 10–⁶ 5
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 BTN3A2 2·36 × 10–¹¹ 5
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 CDSN 1·14 × 10–⁶ 5
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 HLA-C 6·60 × 10–²⁰ 5
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 HLA-DRB1 2·72 × 10–⁶ 5
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 HLA-DRB3 4·47 × 10–⁴⁴ 5
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 HLA-DRB6 1·36 × 10–⁵ 5
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 PSORS1C1 3·27 × 10–¹⁴ 5
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 TUBB 2·94 × 10–⁸ 5
6p21.33 rs2857595 6p21.33 FEV1/FVC 2·28 × 10–¹⁰ NCR3 ZFP57 8·56 × 10–¹⁵ 5
6q24.1 rs3817928 6q24.1 FEV1/FVC 1·17 × 10–⁹ ADGRG6 (GPR126) ·· ·· 6
6q24.1 rs7776375 6q24.1 FEV1/FVC 6·71 × 10–⁹ ADGRG6 (GPR126) ·· ·· 6
6q24.1 rs6937121 6q24.1 FEV1/FVC 1·25 × 10–⁸ ADGRG6 (GPR126) ·· ·· 6
6q24.1 rs11155242 6q24.1 FEV1/FVC 1·45 × 10–⁷† ADGRG6 (GPR126) ·· ·· 6
9q22.32 rs16909898 9q22.32 FEV1/FVC 5·34 × 10–⁷† PTCH1 ·· ·· 6
9q22.32 rs10512249 9q22.32 FEV1/FVC 5·75 × 10–⁷† PTCH1 ·· ·· 6
10p13 rs7068966 10p13 FEV1/FVC and 
FEV1
6·13 × 10–¹³ CDC123 CAMK1D 9·65 × 10–¹⁸ 5
10p13 rs7068966 10p13 FEV1/FVC and 
FEV1
6·13 × 10–¹³ CDC123 CDC123 9·78 × 10–⁷ 5
10q22.3 rs11001819 10q22.3 FEV1 2·98 × 10–¹² C10orf11 C10orf11 1·05 × 10–⁸ 5
12q13.3 rs11172113 12q13.3 FEV1/FVC 1·24 × 10–⁸ LRP1 STAT6 3·31 × 10–¹¹ 5
12q23.1 rs1036429 12q23.1 FEV1/FVC 2·3 × 10–¹¹ CCDC38 SNRPF 4·70 × 10–¹⁶ 5
15q23 rs12899618 15q23 FEV1/FVC 7·24 × 10−¹⁵ THSD4 ·· ·· 4
16q21 rs12447804 16q21 FEV1/FVC 3·59 × 10–⁸ MMP15 ·· ·· 5
16q23.1 rs2865531 16q23.1 FEV1/FVC 1·77 × 10–¹¹ CFDP1 ·· ·· 5
21q22.11 rs9978142 21q22.11 FEV1/FVC 2·65 × 10–⁸ KCNE2 ·· ·· 5
The table reports lung eQTL results for genome-wide associated SNPs (listed by locus) in the three published FEV1 and FEV1/FVC consortia manuscripts.4–6 Gene names shown 
in parentheses are previous gene symbols or synonyms. FEV1=forced expiratory volume in 1 s. FEV1/FVC=ratio of FEV1 to forced vital capacity. GWAS=genome-wide 
association studies. SNP=single nucleotide polymorphisms. ··=SNP is not a lung eQTL at the 10% FDR. *Denotes the GWAS p value from the meta-analysis of discovery and 
replication stages. †Denotes that the SNP achieved genome-wide signiﬁ cance in the discovery cohort only in the CHARGE study. ‡SNP rs2070600 was also reported in the 
CHARGE study6 (p=3·15 × 10–¹⁴ for association with FEV1/FVC). eQTLs=expression quantitative trait loci.
 Table 3: Results of integrating lung eQTLs with FEV1 and FEV1/FVC GWAS reported associations in the SpiroMeta and CHARGE consortia reports4–6
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including both cis and trans, was accounted for. Of these, 
193 (22%), which mapped to 134 genes, showed signiﬁ cant 
associations of lung mRNA levels with either FEV1 or 
FEV1/FVC (at nominal p values of p<0·05) in 
727 participants from the lung eQTL study (table 4 and 
appendix pp 116–145). The expression of genes such as 
SLC35A1, ARIH2, ZNRD1, PADI2, PABPC4, TRIM38, 
LINC00310, SPINK6, PTCH1, and TGFB2 showed the 
strongest associations with lung function. These genes 
are regulated by eSNPs that fell below genome-wide 
signiﬁ cance in the GWAS (the pGWAS values for these 
eSNPs ranged from 9·78 × 10–⁰⁴ to 1·52 × 10–⁰⁶, and as such 
they did not meet the GWAS cutoﬀ  for signiﬁ cance at 
p<5 × 10–⁸). Furthermore, the Q-Q plots (appendix p 14) 
show a systematic deviation of lung function eSNP-
regulated probe set associations with FEV1 and FEV1/FVC 
compared with the expected distribution under the null 
hypothesis of no association. This ﬁ nding is expected in 
view of how these genes were identiﬁ ed; by GWAS and 
lung eQTL analyses, and the deviation supports the 
integrative approach for ﬁ nding genes that underlie the 
phenotype. For 56% of the lung function eSNP-regulated 
probe sets, the direction of eﬀ ect in the eQTL participants 
was concordant with the expected ﬁ nding. The 
concordance at diﬀ erent pGWAS cutoﬀ s remained modest 
(appendix p 146).
The identiﬁ cation of eSNPs helps unravel interesting 
biological relations, such as the signiﬁ cant interaction 
detected on lung function between eSNPs for the 
receptor encoding gene PTCH1 and its ligand competitor 
encoding HHIP (appendix p 24). Additionally, eSNPs in 
the HHIP locus were in high linkage disequilibrium 
with two functional SNPs identiﬁ ed in vitro by Zhou and 
colleagues30 to regulate the expression of HHIP 
(appendix pp 147–148). Furthermore, lung eSNPs in the 
4q31 (HHIP) and 15q25 (CHRNA3/5) loci were also 
recently identiﬁ ed by Castaldi and colleagues as COPD 
eSNPs in blood and sputum tissues (appendix p 149).31
The appendix (p 15) shows a Circos plot32 to summarise 
results from the multiple associations for lung function 
eSNPs: the GWAS p values, lung eQTL p values, and the 
p values for the lung mRNA associations with FEV1 and 
FEV1/FVC in the lung eQTL study.
Lung function eSNPs were associated at GWAS Catalog 
p values ranging from 9 × 10–⁶ to 4 × 10–¹⁸⁶ with several 
diseases and traits (appendix pp 150–204) that can be 
broadly classiﬁ ed into four categories: (1) inﬂ ammatory 
(including asthma, ulcerative colitis, type 1 diabetes, 
leprosy, C reactive protein levels); (2) developmental 
(including age at menopause, bone mineral density, age at 
onset of menarche, height, and primary tooth 
development); (3) neuropsychiatric (including schizo-
phrenia, autism, Parkinson’s disease, bipolar disorder, 
nicotine dependence, smoking behaviour); and 
(4) cardiovascular and obesity-related traits. 
By use of ChIP-Seq data from the ENCODE project, 
lung function eSNP-regulated genes were seen to be 
enriched (at FDR <0·05) in binding sites for several 
transcription factors. The top ranked transcription 
factors are c-Myc, NF-κb, P300, Pol2, Ebf1, and Sin3a. At 
the SNP level, lung function eSNPs were associated with 
several ENCODE functional annotations consistent with 
their role as regulatory SNPs. The enhancer and DNA 
hypersensitivity site enrichment for FEV1 and FEV1/FVC 
cis-eSNPs are shown in the appendix (pp 16–20). 
Additional results and discussion of integration of lung 
eQTL results with ENCODE data are provided in the 
appendix (p 23 and pp 205–209).
To gain insights and generate hypotheses about 
potential therapeutic agents for COPD, the mRNA levels 
of lung function eSNP-regulated genes were tested for 
association with COPD in individuals from the eQTL 
study (appendix pp 209–233). The resulting COPD gene 
Figure 3: Gene ontology enrichment analyses of lung tissue eSNP-regulated 
genes
The graph shows the enriched gene ontology processes on the y axis and their 
corresponding FDR-adjusted p values for enrichment on the x axis. There were 
no signiﬁ cant gene ontology processes enriched among FEV1 and FEV1/FVC 
trans-regulated genes. FDR=false discovery rate. FEV1=forced expiratory volume 
in 1 s. FEV1/FVC=ratio of FEV1 to forced vital capacity. SNP=single nucleotide 
polymorphisms.
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GWAS 
p value
eQTL 
p value
Probe set ID Gene Symbol Expected 
direction*
Expected vs 
observed 
direction†
FEV1 beta‡ FEV1 SE§ FEV1 
p value
FEV1/FVC 
beta¶
FEV1/FVC 
SE||
FEV1/FVC 
p value
FEV1 cis
rs4489748 3·43 × 10–⁴ 1·79 × 10–²³ 100122809_TGI_at ROM1 Negative Concordant –1·54 0·42 2·21 × 10–⁰⁴ –15·55 7·81 4·64 × 10–²
rs17339831 9·45 × 10–⁴ 3·22 × 10–²⁷ 100122984_TGI_at NR3C1 Negative Discordant 0·13 0·035 1·92 × 10–⁰⁴ 1·69 0·63 7·56 × 10–³
rs17339831 9·45 × 10–⁴ 5·24 × 10–¹³ 100129487_TGI_at NR3C1 Negative Discordant 0·15 0·0406 1·42 × 10–⁰⁴ 1·88 0·74 1·12 × 10–²
rs3824658 6·74 × 10–⁴ 1·90 × 10–¹⁵ 100132638_TGI_at ITIH5 Negative Discordant 0·29 0·084 5·56 × 10–⁰⁴ 5·929 1·56 1·49 × 10–⁴
rs17638781 6·21 × 10–⁴ 8·23 × 10–⁸ 100137671_TGI_at SPINK6 Negative Concordant –6·84 1·90 3·15 × 10–⁰⁴ –117·50 34·24 6·01 × 10–⁴
rs1264709 5·18 × 10–⁴ 1·38 × 10–⁸ 100158228_TGI_at ZNRD1 Positive Discordant –0·69 0·18 1·18 × 10–⁰⁴ –12·97 3·26 7·08 × 10–⁵
rs2293476 9·58 × 10–⁴ 2·01 × 10–⁸ 100302787_TGI_at PABPC4 Positive Discordant –0·12 0·03 3·59 × 10–⁰⁴ –2·42 0·61 7·70 × 10–⁵
rs3932521 6·81 × 10–⁴ 1·08 × 10–⁵ 100306590_TGI_at SLC35A1 Positive Concordant 0·22 0·055 4·46 × 10–⁰⁵ 3·06 1·00 2·17 × 10–³
rs2804529 8·18 × 10–⁴ 6·24 × 10–⁶ 100309207_TGI_at VDAC2 Negative Concordant –0·17 0·05 4·97 × 10–⁰⁴ –1·77 0·92 5·51 × 10–²
rs8897 9·61 × 10–⁴ 1·72 × 10–¹³ 100314021_TGI_at ARIH2 Positive Discordant –0·43 0·121 1·67 × 10–⁰⁴ –3·57 2·11 9·05 × 10–²
FEV1 trans
rs1794282 9·70 × 10–⁴ 1·22 × 10–¹⁰ 100126143_TGI_at APOM Positive Concordant 0·67 0·40 9·46 × 10–² –5·90 7·22 4·14 × 10–¹
rs3093975 2·54 × 10–⁴ 9·54 × 10–¹¹ 100139688_TGI_at HCG18 Positive Concordant 0·16 0·09 8·33 × 10–² 1·86 1·69 2·72 × 10–¹
rs9257744 7·61 × 10–⁴ 4·82 × 10–¹⁶ 100143968_TGI_at ZNF323 Negative Discordant 0·13 0·06 4·65 × 10–² 1·43 1·16 2·18 × 10–¹
rs199439 4·72 × 10–⁴ 5·86 × 10–¹² 100300682_TGI_at BRWD1 Negative Discordant 0·59 0·38 1·16 × 10–¹ 11·09 6·81 1·03 × 10–¹
rs9257744 7·61 × 10–⁴ 9·21 × 10–¹⁶ 100301615_TGI_at ZSCAN31 
(ZNF323) 
Negative Discordant 0·13 0·057 2·45 × 10–² 1·39 1·03 1·78 × 10–¹
rs13193532 1·16 × 10–⁵ 1·30 × 10–⁵⁶ 100303994_TGI_at ZFP57 Negative Concordant –0·57 0·27 3·37 × 10–² –8·12 4·95 1·01 × 10–¹
rs3130825 7·60 × 10–⁴ 7·39 × 10–¹² 100308127_TGI_at HCG18 Positive Concordant 0·34 0·16 3·97 × 10–² 3·87 3·004 1·97 × 10–¹
rs538628 4·90 × 10–⁴ 2·55 × 10–²⁸⁴ 100308628_TGI_at LRRC37A4 Positive Concordant 0·10 0·06 6·30 × 10–² 1·78 1·00 7·40 × 10–²
rs9468413 7·06 × 10–⁶ 2·20 × 10–¹⁰ 100311443_TGI_at LRRC16A Positive Concordant 0·60 0·38 1·22 × 10–¹ 1·90 7·00 7·86 × 10–¹
rs3130453 8·58 × 10–⁴ 3·52 × 10–¹¹ 100311825_TGI_at HLA-F-AS1 Negative Concordant –0·7 0·31 2·46 × 10–² –15·69 5·61 5·17 × 10–³
FEV1/FVC cis
rs9467772 8·22 × 10–⁴ 1·55 × 10–⁵ 100127556_TGI_at TRIM38 Positive Discordant –0·16 0·06 4·87 × 10–³ –3·85 1·03 1·96 × 10–⁴
rs2834440 1·55 × 10–⁴ 4·19 × 10–⁵ 100128165_TGI_at LINC00310 
(C21orf82) 
Negative Concordant –3·038 0·86 4·31 × 10–⁴ –51·77 15·71 9·83 × 10–⁴
rs17638781 9·78 × 10–⁴ 8·23 × 10–⁸ 100137671_TGI_at SPINK6 Negative Concordant –6·848 1·90 3·15 × 10–⁴ –117·50 34·25 6·01 × 10–⁴
rs10512248 9·27 × 10–⁵ 1·11 × 10–⁵ 100141529_TGI_at PTCH1 Positive Concordant 0·888 0·31 4·43 × 10–³ 19·17 5·59 6·07 × 10–⁴
rs2235910 1·33 × 10–⁴ 2·28 × 10–⁴³ 100143443_TGI_at PADI2 Negative Concordant –0·068 0·02 5·68 × 10–⁴ –1·24 0·31 7·56 × 10–⁵
rs925284 9·79 × 10–⁴ 8·83 × 10–⁶ 100154282_TGI_at HOXB7 Negative Concordant –0·56 0·20 4·18 × 10–³ –10·74 3·52 2·27 × 10–³
rs3094622 4·47 × 10–⁴ 1·31 × 10–⁷ 100158228_TGI_at ZNRD1 Positive Discordant –0·69 0·18 1·18 × 10–⁴ –12·97 3·26 7·08 × 10–⁵
rs2834463 6·64 × 10–⁴ 9·42 × 10–¹⁰ 100301107_TGI_at LINC00310 
(C21orf82) 
Negative Concordant –1·16 0·52 2·42 × 10–² –32·48 9·30 4·79 × 10–⁴
rs12037222 1·54 × 10–⁴ 2·67 × 10–⁹ 100302787_TGI_at PABPC4 Positive Discordant –0·12 0·03 3·59 × 10–⁴ –2·43 0·61 7·70 × 10–⁵
rs1481345 1·52 × 10–⁶ 2·79 × 10–⁶ 100303767_TGI_at TGFB2 Negative Discordant 0·27 0·10 8·93 × 10–³ 5·81 1·83 1·48 × 10–³
FEV1/FVC trans
rs13193532 7·71 × 10–⁴ 2·73 × 10–¹⁸ 100123483_TGI_at HCG4P6 Negative Concordant –1·29 1·4 3·70 × 10–¹ –51·55 25·90 4·65 × 10–²
rs1264376 5·33 × 10–⁴ 4·91 × 10–¹⁰ 100141210_TGI_at ·· Positive Concordant 0·47 0·30 1·13 × 10–¹ 11·88 5·40 2·78 × 10–²
rs4713279 7·06 × 10–⁴ 4·88 × 10–¹⁰ 100155331_TGI_at ·· Positive Concordant 0·32 0·15 3·52 × 10–² 5·49 2·80 5·14 × 10–²
rs1491106 6·02 × 10–⁵ 4·00 × 10–²⁰ 100161662_TGI_at RBP2 Positive Concordant 0·06 0·08 4·55 × 10–¹ 2·93 1·53 5·53 × 10–²
rs3132450 6·75 × 10–⁵ 7·20 × 10–¹⁶ 100300398_TGI_at HLA-DQB1 Positive Discordant –0·0006 0·006 9·25 × 10–¹ –0·18 0·11 9·92 × 10–²
rs13193532 7·71 × 10–⁴ 1·30 × 10–⁵⁶ 100303994_TGI_at ZFP57 Negative Concordant –0·57 0·27 3·37 × 10–² –8·12 4·95 1·01 × 10–¹
rs3132450 6·75 × 10–⁵ 4·78 × 10–¹⁶ 100304009_TGI_at HLA-DQB1 Positive Discordant –0·0005 0·006 9·29 × 10–¹ –0·17 0·11 1·02 × 10–¹
rs1264376 5·33 × 10–⁴ 3·07 × 10–¹¹ 100304197_TGI_at Positive Concordant 0·29 0·20 1·55 × 10–¹ 7·84 3·71 3·48 × 10–²
rs1491106 6·02 × 10–⁵ 9·92 × 10–¹⁹ 100309242_TGI_at RBP2 Positive Concordant 0·09 0·09 3·03 × 10–¹ 3·62 1·62 2·54 × 10–²
rs3131784 8·63 × 10–⁴ 1·93 × 10–¹⁷ 100311825_TGI_at HLA-F-AS1 Negative Concordant –0·70 0·31 2·46 × 10–² –15·69 5·61 5·17 × 10–³
Gene names shown in parentheses are previous gene symbols or synonyms. *The direction of eﬀ ect inferred from the SNP’s association with lung function and mRNA expression. †Indicates whether the 
observed direction of eﬀ ect of mRNA versus lung function in the 727 participants from the eQTL study was concordant or discordant with the expected direction. ‡Eﬀ ect estimate of probe set’s regression on 
FEV1. §Standard error of probe set›s regression on FEV1. ¶Eﬀ ect estimates of probe set’s regression on FEV1/FVC. ||Standard error of probe set’s regression on FEV1/FVC. eQTLs=expression quantitative trait loci. 
FEV1=forced expiratory volume in 1 s. FEV1/FVC=ratio of FEV1 to forced vital capacity. GWAS=genome-wide association studies. ID=identiﬁ er. SNP=single nucleotide polymorphisms.
Table 4: Results of lung function eSNP-regulated genes’ mRNA regression on FEV1 and FEV1/FVC in 727 participants from the lung eQTL study
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signature was then used to query the Connectivity Map 
database of drug gene expression proﬁ les to identify 
potential COPD therapeutics. Several agents had a 
negative enrichment score suggesting that they are 
predicted to reverse the COPD gene signature. These 
agents included the local anaesthetic and non-selective 
nicotinic receptor blocker adiphenine; disulﬁ ram, which 
is used as a treatment for alcohol dependence and as a 
possible treatment for cocaine dependence; 
perphenazine, a dopamine D1 and D2 receptor 
antagonist; GABAA receptor antagonists (SR-95531; 
Gabazine), and anti-inﬂ ammatory and antioxidant agents 
(hecogenin and withaferin A). Among the agents that 
had a positive enrichment score (ie, predicted to induce 
COPD) were vorinostat and trichostatin A, both of which 
act as histone deacetylase inhibitors; alsterpaullone, a 
cyclin-dependent kinase inhibitor; and the chemo-
therapeutic agent doxorubicin (appendix pp 234–235).
Discussion
Studies of genetic associations and examination of gene 
expression in relevant tissues are important steps in 
unravelling the molecular mechanisms underlying 
common diseases. In this study, a systems genetics 
approach was used to integrate the largest published 
GWAS on the two major lung function parameters used 
clinically—FEV1 and FEV1/FVC—with a powerful lung 
tissue eQTL resource. The main ﬁ ndings are that lung 
function associated SNPs are enriched for lung eQTLs 
and vice versa; integration identiﬁ es the speciﬁ c genes 
that are more likely to be responsible for the GWAS 
signal; lung function eSNP-regulated genes in lung tissue 
are involved in developmental and inﬂ ammatory 
pathways whereas lung function eSNP-regulated genes in 
PBMCs are associated only with inﬂ ammatory pathways; 
and the importance of developmental pathways is 
emphasised by the strong overrepresentation of lung 
function eSNP-regulated genes among genes that are 
diﬀ erentially expressed during fetal lung development. 
Additionally, we noted that the associations of mRNA 
levels of lung function eSNP-regulated genes with lung 
function showed stronger associations to what is expected 
by chance in individuals from the lung eQTL study, and 
in-silico analysis showed that several compounds are 
predicted to reverse (nicotine receptor antagonists) or to 
induce (histone deacetylase inhibitors) the COPD gene 
signature and could guide discovery of new therapeutics.
Restricting susceptibility loci to those that achieve 
genome-wide signiﬁ cance in GWAS is recognised as 
overly conservative; however, including SNPs with 
higher p values will identify false-positive associations 
unless there is additional evidence to implicate these 
variants.33 We chose to interrogate all SNPs with 
pGWAS<0·001, because this threshold might uncover 
biologically relevant yet statistically modest associations. 
The usefulness of this approach is suggested by the fact 
that 47% of the SNPs associated with FEV1 and 42% of 
the SNPs associated with FEV1/FVC were cis-acting or 
trans-acting eSNPs. This ﬁ nding represents substantial 
enrichment since only 18% and 0·6% of all SNPs acted 
as cis and trans lung eQTLs, respectively.
The discovery of eSNPs could help to identify genes in 
causal pathways, especially in regions containing 
multiple genes. For example, intronic SNP rs10516526 in 
GSTCD on chromosome 4q24, which showed one of the 
strongest associations with FEV1 (p=4·75 × 10–¹⁴) maps to 
a linkage disequilibrium rich region containing the 
GSTCD, INTS12, and NPNT genes. In lung tissue, 
rs10516526 is an eQTL for NPNT but not for GSTCD or 
INTS12. However, in PBMCs28 and lymphoblastoid cell 
lines,15 the same SNP is an eQTL for INTS12, reﬂ ecting 
the tissue speciﬁ city of eQTLs. These results suggest that 
one mechanism through which this susceptibility locus 
could have its eﬀ ect is through modulation of the lung 
tissue levels of NPNT, a conclusion strengthened by the 
association between FEV1/FVC and mRNA levels for 
NPNT in the lung eQTL participants (p=0·01) and by the 
strong NPNT staining of pulmonary endothelial cells 
and alveolar epithelial cells (appendix p 21).
The identiﬁ cation of trans-eSNPs in particular reveals 
novel genes that would not be implicated because of their 
genomic position. An example is the retinol binding 
protein (RBP2; appendix p 23). Alternatively, integration 
of GWAS and eQTL results provides additional support 
for commonly associated genes. For example, the 
intergenic SNP rs13141641 on 4q31, which showed one of 
the strongest GWAS associations with FEV1/FVC 
(p=8·451 × 10–¹⁸) is a lung (but not blood) eQTL for HHIP. 
HHIP eSNPs identiﬁ ed in this study were in strong 
linkage disequilibrium with functional SNPs reported by 
Zhou and colleagues30 to aﬀ ect the expression of HHIP 
in vitro (appendix pp 147–148).
HHIP blocks the hedgehog signalling pathway by 
binding to PTCH1 ligands, a membrane receptor for the 
hedgehog (HH) proteins, Sonic (SHH), Desert (DHH), 
and Indian hedgehog (IHH). Interestingly, a SNP 
(rs10512248) in PTCH1 was associated with FEV1/FVC 
(p=9·2 × 10–⁰⁵) and is an eQTL for PTCH1 (p=1·1 × 10–⁰⁵). 
The availability of eQTL data thus allows the suggestion 
of a biologically plausible causal pathway for the 
PTCH1/HHIP combination of susceptibility alleles. 
The HHIP allele that is associated with lower lung 
function substantially increases the mRNA levels of 
HHIP, suggesting that decreased hedgehog signalling 
adversely aﬀ ects lung development. Similarly, the 
PTCH1 allele that is associated with lower lung function 
substantially decreases the expression of the receptor, 
which would also be expected to decrease hedgehog 
signalling. There was a strong interaction between the 
HHIP and PTCH1 eSNPs on FEV1 and FEV1/FVC in the 
participants of the eQTL study (appendix p 22 and p 24). 
The availability of mRNA data from the lung tissue 
samples of the participants of the eQTL study provides 
additional support for this pathway; higher levels of 
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HHIP (p=0·01 for FEV1 and p=0·003 for FEV1/FVC) 
and lower levels of PTCH1 (p=0·004 for FEV1 and 
p=0·0006 for FEV1/FVC) were associated with worse 
lung function in this cohort. Lung function eSNP-
regulated genes derived from analysis of lung tissue, and 
to a lesser extent, lung function eSNP-regulated genes 
derived from the analysis of PBMCs were enriched for 
genes involved in development, maturation, and 
inﬂ ammatory processes. Lung function eSNP-regulated 
genes that were unique only to blood cells were enriched 
for inﬂ ammatory but not developmental processes. 
A link between lung development and growth in utero or 
in infancy and impaired lung function and COPD in 
adults has been previously proposed,34–39 and indeed 
genes determining adult lung function have also been 
associated with reduced airway calibre in early 
childhood.40 The molecular mechanisms explaining this 
link remain poorly understood. Lung function eSNP-
regulated genes such as TGFB2, HHIP, PTCH1, 
NOTCH4, and RBP2 are members of families that are 
well known for their role in lung development and 
growth.34,41–49 Additional support for the role of 
developmental genes as determinants of lung function is 
the ﬁ nding that lung function eSNP-regulated genes 
were enriched among genes that vary in expression 
during human fetal lung development.
Inﬂ ammation was the other enriched pathway. 
Inﬂ ammation is inextricably linked to tissue remodelling 
and repair processes, which can aﬀ ect the lung 
parenchyma and airways to alter lung function.50 
Although inﬂ ammation and lung development could 
operate independently of each other, it is also feasible 
that the two processes interact. Inﬂ ammation may lead 
to activation of tissue repair and remodelling processes 
that reactivate genes involved in lung development and 
growth. Alternatively, genetically determined variation in 
lung development and growth could alter lung structure 
to aﬀ ect particle deposition and the inﬂ ammatory 
response to toxic inhalants, such as tobacco smoke.
In this study, gene expression could be related to lung 
function in the same participants whose lung tissue was 
used to generate the lung eQTL data. The mRNA 
expression of 193 probe sets (22% of all probe sets tested) 
showed signiﬁ cant association with either FEV1 or 
FEV1/FVC at a nominal p value. This level of association 
is more than would be expected by chance as shown in 
the Q-Q plot. Of the 193 probe sets, 109 (56%) showed an 
observed direction of eﬀ ect that was concordant with the 
expected direction of eﬀ ect. There are several potential 
mechanisms that could explain discordant relations for 
the other 84 probe sets (44%). First, changes in gene 
expression may be a response to the disease process and 
the magnitude of this response may overwhelm the eﬀ ect 
of the eSNP. Second, although the expected direction is 
based on the eﬀ ect of the top eSNP for that gene, the 
same gene could also be under genetic control of other 
weaker eSNPs that collectively have an opposite direction 
of eﬀ ect. Third, epigenetic modiﬁ cations or microRNAs 
could also aﬀ ect the levels of expression. Finally, the 
relation could simply be a false-positive ﬁ nding, in view 
of our relaxed nominal p values threshold.
The identiﬁ cation of genes that underlie lung function 
variation in lung tissue could be an essential step for 
COPD drug and biomarker development. In-silico drug 
repositioning can identify existing drugs that recapitulate 
or reverse the gene signature associated with COPD. 
Such screening has proven to be a valuable method for 
drug repurposing.51–53 The Connectivity Map data suggest 
that vorinostat and trichostatin A, both of which act as 
histone deacetylase inhibitors, can reproduce the COPD 
gene signature. Histone deacetylase activators such as 
theophylline have been suggested as a treatment for 
COPD, especially in combination with corticosteroids.54 
Trichostatin A has also been shown to cause emphysema 
in rats, and was associated with decreased vascular 
endothelial growth factor (VEGF) expression.55 Another 
Connectivity Map candidate inducer of COPD, 
alsterpaullone, downregulates VEGF and ﬁ broblast 
growth factor.56 Connectivity Map analysis showed several 
compounds that reversed the COPD gene signature, 
including adiphenine, a local anaesthetic that non-
selectively inhibits at least four diﬀ erent nicotinic 
acetylcholine receptor (nAChR) subtypes.57,58 SNPs at the 
15q25 locus containing genes encoding the nAChRs 
CHRNA3 and CHRNA5 have been associated with lung 
cancer, COPD, and lung function.59–62 nAChR in the lung 
has been reported to have a role in cell proliferation and 
apoptosis in response to carcinogens,63,64 as well as in 
inﬂ ammation.65 Other compounds that reverse the COPD 
gene signature aﬀ ect dopamine; these include disulﬁ ram, 
which is used as a treatment for alcohol dependence and 
is being explored for use in cocaine dependence.66 
Disulﬁ ram inhibits dopamine β-hydroxylase, which 
converts dopamine to norepinephrine.66 Perphenazine is 
an antagonist of dopamine D1 and D2 receptors,67 which 
also binds to the α-adrenergic receptor.68 One study 
suggested that dopamine receptor and transporter genes 
(DRD2 and SLC6A3) might have a role in the progression 
of COPD.69
To our knowledge, this study is the ﬁ rst to report large-
scale integration of lung function GWAS and lung 
eQTLs. The datasets used are the largest so far and the 
results represent a resource to the scientiﬁ c community 
as a whole. The availability of lung tissue mRNA levels, 
eQTLs, and lung function measures on the same 
individuals provided a unique complementary resource 
to lung function GWAS ﬁ ndings, and aids the translation 
of SNP associations into actionable targets.
Our study has some limitations. First, such large-scale 
integration of GWAS and eQTLs can lead to coincidental 
overlap that is not necessarily reﬂ ective of disease biology. 
Recent methods have been proposed to integrate GWAS 
and eQTLs such as colocalisation,70 a weighted approach,71 
and signature matching.72 Additionally, as the number of 
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respiratory-related tissue eQTLs increases, approaches 
employing joint analysis of eQTLs in multiple tissues73 will 
be needed to increase power. Second, although the eQTL 
discovery and mRNA associations were adjusted for 
smoking status, this adjustment could have undermined 
the power to detect SNPs and mRNAs that show markedly 
diﬀ erent associations in smokers versus non-smokers 
(interaction). Additionally, no adjustments for pack-years 
were made. Projects that investigate these relations 
represent future avenues to follow up ﬁ ndings from this 
study. Finally, the Connectivity Map drug gene expression 
proﬁ les were measured in non-respiratory cancer cell 
lines, which could be diﬀ erent from lung or airway-related 
expression proﬁ les. Similar drug repurposing approaches 
in respiratory-related cells or tissues are warranted.
In summary, the systems genetics approach identiﬁ ed 
genes and molecular mechanisms that underlie the 
variation in lung function measures, generating 
hypotheses for future in-vitro and in-vivo studies. This 
study emphasises the importance of lung development 
and inﬂ ammatory pathways for lung function variation in 
adults. The ﬁ nding that existing drugs can reverse the 
lung tissue gene signature associated with airﬂ ow 
obstruction suggests attractive candidates for interfering 
with the pathogenesis of COPD.
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